Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?
Greaves
Mike
M
School of Medicine, University of Aberdeen, Aberdeen, United Kingdom. m.greaves@abdn.ac.uk
D000925:Anticoagulants / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003374:Coumarins / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance / Q000235:genetics; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D013923:Thromboembolism / Q000517:prevention & control; D064417:Vitamin K Epoxide Reductases
D000925:Anticoagulants; D003374:Coumarins; C030123:coumarin; D006899:Mixed Function Oxygenases; D064417:Vitamin K Epoxide Reductases